VCAM-targeted delivery of recombinant CD39 to the endothelium is antithrombotic, antiinflammatory and ameliorates ischaemia reperfusion injury.

VCAM 靶向递送重组 CD39 至内皮细胞具有抗血栓、抗炎和改善缺血再灌注损伤的作用。

• 批准号: nhmrc : GNT1083006
• 负责人: Prof Harshal Nandurkar
• 金额: $ 60.38万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/vcam-targeted-delivery-reperfusion-injury/1345481
• 关键词: VCAM; targeted; delivery; recombinant; CD39

Blockage of arteries with clots leads to heart attacks and strokes. Reestablishment of blood supply by clot-busting drugs or mechanical interventions paradoxically causes further organ injury. This is due to toxic chemicals generated by inflammatory processes and free oxygen radicals. We have created an unique drug that selectively targets blood vessels that are injured by process. The drug will deliver blood-thinning activity and reduce inflammatory stress selectively at the site of need.

血栓阻塞动脉会导致心脏病发作和中风。通过血栓破坏药物或机械干预重建血液供应矛盾地导致进一步的器官损伤。这是由于炎症过程和自由氧自由基产生的有毒化学物质。我们已经创造了一种独特的药物，选择性地针对血管的过程中受伤。该药物将提供血液稀释活性，并在需要的部位选择性地减少炎症应激。